Key result
Genetically decreased serum ACE levels show no link to COVID-19 susceptibility, hospitalization, or severity.
Why the study?
Uncertainty existed regarding the safety or benefit of ACE inhibitors during the COVID-19 pandemic, motivating testing of whether decreased ACE levels increase SARS-CoV-2 susceptibility or severity.
Does genetically decreased serum ACE level increase COVID-19 susceptibility or severity in the general population?
Population
Up to 960 186 individuals of European ancestry
Comparison
Genetically decreased serum ACE levels vs baseline
Design
Mendelian randomization study
Authors
Loading...
Genetically lower ACE levels show no COVID-19 link; leaves open ACE inhibitor effects pending randomized confirmation.
Observational (n=960,186)
Mendelian randomization
Yes
Does genetically decreased serum ACE level increase COVID-19 susceptibility or severity in the general population?
Effect estimate: OR 1.02 (95% CI 0.90-1.15)
Genetically decreased serum ACE levels do not increase the risk of COVID-19 susceptibility or severity, supporting the safety of continuing ACE inhibitors during the pandemic.
Butler‐Laporte et al. (2020) conducted an observational in COVID-19 (n=960,186). Genetically decreased serum ACE levels was evaluated on COVID-19 susceptibility (OR 1.02, 95% CI 0.90-1.15). Genetically decreased serum ACE levels were not associated with increased COVID-19 susceptibility (OR 1.02; 95% CI 0.90-1.15), hospitalization, or severe disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: